

PROVECTUS BIOPHARMACEUTICALS, INC.

Form 8-K/A

March 16, 2015

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 16, 2015

PROVECTUS BIOPHARMACEUTICALS, INC.

(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction

of incorporation)

001-36457
(Commission

File Number)

7327 Oak Ridge Hwy., Knoxville, Tennessee 37931

90-0031917
(IRS Employer

Identification No.)

(Address of Principal Executive Offices)

(866) 594-5999

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Explanatory Note.

On March 16, 2015, Provectus Biopharmaceuticals, Inc. (the Company) filed a Form 8-K (the Original Filing) relating to the Company's announcement regarding its amended protocol for the Company's phase 3 study of PV-10 as a treatment for melanoma. This Form 8-K/A is filed to correct a typographical error regarding the availability of the amended protocol. For convenience, we have included in this filing the entirety of the Original Filing, as amended, to correct the typographical error.

Item 7.01. Regulation FD Disclosure.

On March 16, 2015, the Company issued a press release (the Press Release) announcing that the amended protocol for the Company's phase 3 study of PV-10 as a treatment for melanoma is now available at <http://clinicaltrials.gov/ct2/show/study/NCT02288897>. The Company does not require additional review from the U.S. Food and Drug Administration to begin its phase 3 study, and has begun the process of gaining approval from the Institutional Review Board for each site in the study for the amended protocol. A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated into this Item 7.01 by reference.

Pursuant to the rules and regulations of the Securities and Exchange Commission, the information in this Item 7.01 disclosure, including Exhibit 99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be filed under the Securities Exchange Act of 1934.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Press Release, dated March 16, 2015

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 16, 2015

**PROVECTUS BIOPHARMACEUTICALS,
INC.**

By: /s/ Peter R. Culpepper
Peter R. Culpepper
Chief Financial Officer and Chief
Operating Officer

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release, dated March 16, 2015